Investment Rating - The industry rating for the media and internet sector is "Positive" [2][47] Core Insights - Kuaishou's AI product, Keling, achieved a significant milestone with over 12 million monthly active users (MAU) in January 2026, and daily revenue increased by approximately 30% month-on-month [3][4] - The animation drama market is projected to reach 22 billion yuan in 2026, contributing 50% to the short drama industry's growth, with a compound annual growth rate (CAGR) of 12% for user scale and 24% for viewership from June to December 2025 [3][4] - AI technology is being increasingly applied in various stages of animation production, leading to over 70% cost reduction and over 80% efficiency improvement [4] Summary by Sections Sub-industry Ratings - The film industry is rated as "Positive" [2] User and Revenue Growth - Kuaishou's Keling AI user base and revenue have shown breakthrough performance, with a monthly revenue exceeding 20 million USD in December 2025 and a 350% increase in monthly paid users [3][4] Market Size and Growth Projections - The animation drama market is expected to exceed 22 billion yuan in 2026, with AI-generated content gaining significant viewer acceptance [3][4] AI Application in Content Creation - AI is utilized in creative processes, content production, and editing operations, with application ratios ranging from 10%-30% in creativity to 50%-80% in content production [4] Recommendations - The report suggests paying attention to companies like Bona Film Group due to their potential in the evolving landscape of AI-driven content production [4]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.26% on January 23, 2025, outperforming the CSI 300 index by 1.71 percentage points, ranking 10th among 31 sub-industries in the Shenwan classification. Notable performers included offline pharmacies (+6.79%), pharmaceutical distribution (+2.66%), and vaccines (+2.26%), while blood products (+0.58%), medical R&D outsourcing (+0.68%), and in vitro diagnostics (+1.37%) lagged behind [4]. - Takeda's new drug Oveporexton has been proposed for priority review by the National Medical Products Administration (NMPA) in China, aimed at treating narcolepsy type 1 in patients aged 16 and above. The drug has shown positive results in two pivotal Phase 3 studies [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% compared to the CSI 300 index in the next six months [62]. Core Insights - The company, Kory Technology, is a leader in advanced manufacturing with a focus on cross-industry applications, having evolved from its initial focus on hard disk automation to a global supplier of industrial automation equipment and smart manufacturing solutions [3][4]. - The company's revenue is projected to decline by 14.34% to 2.448 billion yuan in 2024 due to industry cycles, but a recovery is anticipated in 2025 with a slight growth of 0.22% in the first three quarters [3][14]. - The company's gross margin has consistently remained around 35%, indicating strong profitability support [3][14]. Summary by Sections 1. Company Overview - Kory Technology was established in 2001 and has expanded its business into various sectors including mobile terminals, new energy, automotive, and logistics [3][4]. - The company's main business strategy is centered around the "3+N" framework, with three core business areas: mobile terminals, new energy, and precision components, which together accounted for 81.32% of revenue in 2024 [3][18]. 2. Mobile Terminal Business - The mobile terminal sector is expected to benefit from the rapid growth of the AI market, with a projected CAGR of 39.6% from 2025 to 2029 [4][32]. - Kory Technology has established strong partnerships with major clients such as Apple, Google, and Huawei, positioning itself as a leading supplier of testing equipment for mobile devices [38]. 3. New Energy Business - The demand for lithium batteries is expected to grow significantly, with global shipments projected to reach 6012.3 GWh by 2030 [42]. - The company focuses on mid-to-late stage equipment for lithium battery manufacturing, collaborating with leading firms like CATL and EVE Energy [49]. 4. Precision Components Business - Kory Technology's precision components are positioned in the mid-to-high-end market, with applications across various sectors including hard drives and medical devices [55]. - In the first half of 2025, this segment achieved a revenue of 2.33 billion yuan, representing a year-on-year growth of 31.78% [55]. 5. "N" Business Segment - The company is expanding into high-potential areas such as semiconductors and medical technology, benefiting from the acceleration of domestic substitution [59]. - Kory Technology provides ultra-precision components for semiconductor equipment, with capabilities reaching up to 50nm [59].

医药 医药 2026 年 01 月 22 日 行业日报 看好/维持 太平洋医药日报（20260122）：第一三共 ADC 新药 R-DXd 在华获 突破性疗法认定 ◼ 走势比较 (10%) 0% 10% 20% 30% 40% 25/1/22 25/4/5 25/6/17 25/8/29 25/11/10 26/1/22 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260121）：礼来 ADC 药物 LY4170156 获 FDA 突破性疗 法认定>>--2026-01-22 <<太平洋医药日报（20260120）：GSK 将以 22 亿美金收购 RAPT>>--2026- 01-21 <<太平洋医药日报（20260119）：武田 Oveporexton 在 华 申 报 上 市 >>-- 2026-01-20 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 ...

太平洋房地产日报（20260122）：杭州 2026 年首宗宅地挂牌 2026 年 01 月 22 日 行业日报 中性/维持 房地产 房地产 走势比较 (20%) (10%) 0% 10% 20% 30% 25/1/21 25/4/4 25/6/16 25/8/28 25/11/9 26/1/21 子行业评级 | 和运营 | | | --- | --- | | 房 地 产 开 发 房地产服务 | 无评级 无评级 | 推荐公司及评级 相关研究报告 <<太平洋房地产日报（20260121）：26 年南京首拍收金 15.38 亿元>>-- 2026-01-21 <<太平洋房地产日报（20260120）：台 州玉环一宗宅地出让>>--2026-01- 21 <<全年销售延续调整态势，房价环比 降幅小幅收窄>>--2026-01-20 证券分析师：徐超 电话：18311057693 E-MAIL：xuchao@tpyzq.com 分析师登记编号：S1190521050001 证券分析师：戴梓涵 电话：18217681683 E-MAIL：daizh@tpyzq.com 分析师登记编号：S1190524110003 报告 ...

机械 证券研究报告 |公司深度 2026/01/14 科瑞技术(002957)公司深度———— 先进制造跨行业应用龙头，"3+N"战略布 局把握智能制造浪潮 证券分析师: 张世杰(分析师) 证券分析师: 罗平(分析师) 分析师登记编号: S1190523020001 分析师登记编号: S1190524030001 P2 报告摘要 公司概况：先进制造领域的跨行业应用龙头。科瑞技术成立于2001年，初期专注于硬盘行业自动化业务，经过20余年发 展，已成长为工业自动化设备及智能制造解决方案的全球供应商。其业务逐步拓展至移动终端、新能源、汽车、物流等 多个行业，并于2019年实现A股主板上市。主营业务围绕"3+N"战略布局，营收表现较为稳健，2024年受行业周期影响 营收同比下降14.34%至24.48亿元，但2025年前三季度已呈现稳健修复，营收同比增长0.22%。盈利能力方面，公司综合 毛利率长期维持在35%左右的高位水平，具有强劲的支撑。公司三大核心业务主要包括移动终端业务、新能源业务以及 精密零部件业务，2024年三大战略业务收入占比合计81.32%。其中分产品来看，自动化设备是公司营收的主要来源，近 年来始 ...

Investment Rating - The overall industry investment rating is neutral, indicating that the expected return over the next six months is between -5% and 5% relative to the CSI 300 index [10] Core Insights - The household appliance industry experienced a single-digit decline in export value of 7% in December 2025, with specific categories like vacuum cleaners, washing machines, and refrigerators showing growth [4][8] - White goods such as refrigerators and washing machines achieved stable growth of 4% each, while air conditioners and fans faced significant demand pressure with declines of 20% and 28% respectively [4][8] - In the black goods and smart projection segment, projectors saw a double-digit decline of 13%, while the growth rate for LCD TVs turned positive at 5% [4][8] - Kitchen appliances and electrical lighting faced challenges, with range hoods declining by 10% and demand for plugs and sockets stabilizing at a 5% decline [4][8] - Cleaning appliances, particularly vacuum cleaners, maintained a strong growth rate of 14% [4][8] - Small kitchen appliances such as toasters, blenders, microwaves, and coffee machines faced varying degrees of pressure, with declines of 21%, 16%, 10%, and 15% respectively [4][8] - Personal care small appliances like electric shavers showed a need for improvement with a decline of 21%, while hair dryers and irons had reduced declines of 6% each [4][8] Summary by Category - **White Goods**: Refrigerators and washing machines grew by 4% each, while air conditioners and fans declined by 20% and 28% respectively [4][8] - **Black Goods and Smart Projection**: Projectors declined by 13%, while LCD TVs grew by 5% [4][8] - **Kitchen Appliances and Electrical Lighting**: Range hoods declined by 10%, plugs and sockets stabilized with a 5% decline [4][8] - **Cleaning Appliances**: Vacuum cleaners grew by 14% [4][8] - **Small Kitchen Appliances**: Toasters, blenders, microwaves, and coffee machines faced declines of 21%, 16%, 10%, and 15% respectively [4][8] - **Personal Care Small Appliances**: Electric shavers declined by 21%, while hair dryers and irons had reduced declines of 6% each [4][8]

2026 年 01 月 20 日 行业日报 中性/维持 房地产 房地产 太平洋房地产日报（20260120）：台州玉环一宗宅地出让 走势比较 (20%) (10%) 0% 10% 20% 30% 25/1/20 25/4/3 25/6/15 25/8/27 25/11/8 26/1/20 子行业评级 | 和运营 | | | --- | --- | | 房 地 产 开 发 房地产服务 | 无评级 无评级 | 推荐公司及评级 相关研究报告 <<全年销售延续调整态势，房价环比 降幅小幅收窄>>--2026-01-20 <<太平洋房地产日报（20260119）：浙 江金华出让 1 宗低密宅地>>--2026- 01-20 <<太平洋房地产日报（20260114）：青 岛土拍收金10.15亿元>>--2026-01- 15 证券分析师：徐超 电话：18311057693 E-MAIL：xuchao@tpyzq.com 分析师登记编号：S1190521050001 证券分析师：戴梓涵 电话：18217681683 E-MAIL：daizh@tpyzq.com 分析师登记编号：S1190524110003 报告摘要 市场行 ...

Investment Rating - The industry is rated as "positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [7]. Core Insights - The report highlights a significant growth trend in the electronic cigarette sector, with an expected increase of 28% in export value by December 2025. Additionally, the corrugated box category is projected to grow by 12% [1][2]. - The paper industry shows a mixed performance, with corrugated boxes achieving double-digit growth (+12%), while the demand for bleached paper and paperboard has slightly declined (-7%). The performance of pulp and paper products remains stable with a minor decrease of -1% [2][6]. - The home furnishings sector is experiencing a notable decline, particularly in spring mattresses, which are under short-term pressure with a decrease of -3%. Other categories such as bathroom fixtures, office furniture, sofas, and PVC flooring are facing significant demand challenges, with declines ranging from -14% to -28% [2][6]. - The report also notes that other categories, including thermal cups and plastic tableware, are experiencing slight declines of -14% and -9%, respectively, while electronic cigarettes continue to show robust growth [2][6]. Summary by Relevant Sections Paper Industry - Corrugated boxes are expected to see a growth of +12% - Bleached paper and paperboard are facing a decline of -7% - Pulp and paper products are stable with a decrease of -1% [2][6] Home Furnishings - Spring mattresses are under pressure with a decline of -3% - Significant declines in demand for bathroom fixtures (-28%), office furniture (-18%), sofas (-15%), and PVC flooring (-14%) [2][6] Other Categories - Electronic cigarettes are projected to grow by +28% - Thermal cups and plastic tableware are experiencing declines of -14% and -9% respectively [2][6]

Investment Rating - The report gives a "Buy" rating for Dongxing Medical [5] Core Viewpoints - Dongxing Medical is positioned as a micro-invasive surgical platform company with diversified layouts that promote growth. The company focuses on the anastomosis device industry chain and is gradually expanding into other micro-invasive surgical products, aiming to establish itself as a platform enterprise in medical devices [3][12] - The company plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., which has obtained 58 medical device registration certificates, enhancing its medical device platform and facilitating synergistic development [3][12] - The company has a concentrated shareholding structure and a professional management team, with expected revenue growth driven by product upgrades and cost control [3][12] Summary by Sections 1. Company Overview - Dongxing Medical has diversified its business since its establishment in 2001, transitioning from an agency model to a medical device manufacturer. The company has completed several acquisitions to integrate its supply chain, including the acquisition of Weike Medical and Zihang Precision, which closed the anastomosis device industry chain [12][19] - The company has a strong cash position, with cash and cash equivalents reaching 1.2 billion yuan, supporting future acquisitions [30][32] 2. Anastomosis Device Market - The anastomosis device market in China is expected to reach 9.82 billion yuan by 2024, with a compound annual growth rate (CAGR) of 8.1% from 2019 to 2024. The electric laparoscopic anastomosis device market is projected to grow significantly, with a CAGR of 44.4% during the same period [49][52] - The report indicates that the impact of centralized procurement on pricing has reached a turning point, with price adjustments stabilizing and the industry entering a phase of steady growth as penetration rates increase [54][55] 3. New Surgical Products - The company is expanding its product line to include ultrasonic knives, with a market size in the tens of billions. The domestic market for ultrasonic knives is rapidly increasing due to the rise in domestic production rates [5][12] - The company is also collaborating with Shanghai Jiao Tong University to develop synthetic biological materials, which are expected to be applied in serious medical fields such as hemostasis and scar repair, adding another growth point [5][12] 4. Financial Forecast and Valuation - The company forecasts revenues of 379 million yuan, 445 million yuan, and 512 million yuan for 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be -37 million yuan, 94 million yuan, and 121 million yuan for the same years [5][8] - The report estimates a price-to-earnings (PE) ratio of 29x for 2026 based on the closing price on January 16, 2026 [5][8]